论文部分内容阅读
目的:探讨减低硼替佐米剂量治疗多发性骨髓瘤(MM)对疗效的影响。方法:硼替佐米1.0 mg/m2方案治疗MM患者17例,为观察组;硼替佐米1.3 mg/m2方案治疗MM患者16例,为对照组。结果:①治疗2个疗程后,观察组、对照组有效率分别为70.59%和68.75%,两组无显著差异(P>0.05);治疗4个疗程后,两组相比,有效率和完全缓解(CR)率也无显著性差异(P>0.05);②观察组坚持治疗4个疗程的依从性为82.35%,要高于对照组的50%,但无统计学差异;③观察组、对照组治疗4个疗程与2个疗程组内比较,有效率有所增加,无统计学意义(P>0.05),而两组的CR率4个疗程比2个疗程都明显升高(P<0.05),18个月内疾病进展/复发率则明显降低(P<0.01);④不良反应:减低剂量组患者临床不良反应减轻,但与对照组相比无统计学差异。结论:适当减低硼替佐米剂量治疗MM并不影响近期疗效,可能增加患者完成治疗的依从性,从而提高CR率,减少疾病的早期进展与复发。
Objective: To investigate the effect of reducing the dose of bortezomib in the treatment of multiple myeloma (MM). Methods: Bortezomib 1.0 mg / m2 regimen for the treatment of MM patients in 17 cases, the observation group; bortezomib 1.3 mg / m2 regimen in MM patients in 16 cases, as the control group. Results: ① After two courses of treatment, the effective rates in the observation group and the control group were 70.59% and 68.75%, respectively, with no significant difference between the two groups (P> 0.05). After 4 courses of treatment, the efficiency and completeness There was no significant difference in CR rate between two groups (P> 0.05); ② The adherence of the observation group to the four courses was 82.35%, which was higher than that of the control group (50%), but there was no significant difference between the observation group and the observation group There was no significant difference between the 4 treatment courses and the 2 treatment courses in the control group (P> 0.05). However, the CR rates in both groups were significantly higher than those in the 2 courses (P < 0.05). The rate of disease progression / relapse was significantly lower in 18 months (P <0.01). Adverse reactions: The clinical adverse reactions were relieved in the dose-reduced group, but there was no significant difference compared with the control group. Conclusions: Appropriate reduction of bortezomib dose did not affect the short-term efficacy of MM, may increase the compliance of patients to complete the treatment, thereby increasing the CR rate and reduce the disease’s early progress and recurrence.